S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Unity Biotechnology Stock Forecast, Price & News

+0.07 (+12.50%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
505 shs
Average Volume
671,506 shs
Market Capitalization
$43.58 million
P/E Ratio
Dividend Yield
Price Target

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
915.9% Upside
$6.40 Price Target
Short Interest
0.75% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.04mentions of Unity Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$12,055 Sold Last Quarter
Proj. Earnings Growth
From ($1.10) to ($1.28) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.75 out of 5 stars

Medical Sector

797th out of 1,427 stocks

Biotechnology Industry

1st out of 7 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

UBX Stock News Headlines

How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Unity Biotechnology Inc UBX
Unity Biotechnology, Inc. (UBX)
See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$4.78 million


Free Float
Market Cap
$43.58 million
Not Optionable

Unity Biotechnology Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Unity Biotechnology stock.
View analyst ratings for Unity Biotechnology
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2022?

4 equities research analysts have issued 12 month price targets for Unity Biotechnology's shares. Their UBX stock forecasts range from $4.00 to $12.00. On average, they anticipate Unity Biotechnology's stock price to reach $6.40 in the next year. This suggests a possible upside of 915.9% from the stock's current price.
View analysts' price targets for Unity Biotechnology
or view top-rated stocks among Wall Street analysts.

How has Unity Biotechnology's stock price performed in 2022?

Unity Biotechnology's stock was trading at $1.46 at the beginning of 2022. Since then, UBX shares have decreased by 56.8% and is now trading at $0.63.
View the best growth stocks for 2022 here

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Unity Biotechnology

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.
View Unity Biotechnology's earnings history

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Anirvan Ghosh Ph.D., CEO & Director (Age 58, Pay $885.54k)
  • Dr. Nathaniel E. David A.B., Ph.D., Co-Founder & Exec. Director (Age 54, Pay $40k)
  • Ms. Lynne Marie Sullivan, CFO & Head of Corp. Devel. (Age 55, Pay $614.84k)
  • Dr. Jamie Dananberg M.D., Chief Medical Officer (Age 64, Pay $635.79k)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi Ph.D., Founder
  • Mr. Daohong Zhou M.D., Founder
  • Mr. Nathan Guz Ph.D., VP of Operations
  • Mr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 46)
  • Dr. Przemyslaw Sapieha Ph.D., Chief Scientific Advisor

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $0.63.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $43.58 million and generates $4.78 million in revenue each year.

How many employees does Unity Biotechnology have?

Unity Biotechnology employs 65 workers across the globe.

How can I contact Unity Biotechnology?

The official website for Unity Biotechnology is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192.

This page (NASDAQ:UBX) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.